US · AURA
Aura Biosciences, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Boston, MA 02140
- Website
- aurabiosciences.com
Price · as of 2024-12-31
$7.01
Market cap 374.03M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $19.22 | ||||
| 2022 | $10.00 | ||||
| 2023 | $8.38 | ||||
| 2024 | $7.40 |
AI valuation
Our deep-learning model estimates Aura Biosciences, Inc.'s (AURA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $7.01
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AURA | Aura Biosciences, Inc. | $7.01 | 374.03M | — | — | — | — | -4.23 | 2.42 | — | -2.48 | — | 2.42 | 0.00% | — | — | -46.01% | -494.17% | -39.73% | 0.12 | — | 10.77 | 10.13 | 0.14 | -933.00% | — | 2556.00% | -22.06% | -5.35 | -416.75% | 0.00% | 0.00% | 0.00% | -2.45 | -2.90 | — | 3.57 |
| ALT | Altimmune, Inc. | $4.31 | 380.39M | +632% | -46% | — | +2,482% | -4.16 | 3.20 | 19774.45 | -2.80 | — | 3.20 | 100.00% | -515860.00% | -475295.00% | -59.86% | 2117.00% | -54.33% | 0.01 | -11463.56 | 13.11 | 12.90 | 0.37 | -1928.00% | -9531.00% | 526.00% | -20.19% | -7.63 | 1638.41% | 0.00% | 0.00% | 0.00% | -2.57 | -3.32 | 13263.95 | 8.03 |
| ANNX | Annexon, Inc. | $5.60 | 669.73M | — | — | — | — | -2.74 | 1.29 | — | -0.71 | — | 1.29 | 0.00% | — | — | -50.84% | -955.34% | -42.67% | 0.10 | — | 10.37 | 10.23 | 0.15 | -4294.00% | — | -273.00% | -31.12% | -3.87 | -731.80% | 0.00% | 0.00% | 0.00% | -0.62 | -0.82 | — | 0.68 |
| DBVT | DBV Technologies S.A. | $20.99 | 502.12M | -17% | — | — | — | -0.71 | 2.93 | — | -0.50 | -1.28 | 2.94 | 0.00% | — | — | -135.96% | -2872.45% | -91.63% | 0.28 | — | 1.43 | 1.38 | 0.22 | 5526.00% | -10000.00% | 3297.00% | -132.98% | -3.36 | -2637.08% | 0.00% | 0.00% | 0.06% | -0.46 | -0.52 | — | -10.66 |
| DSGN | Design Therapeutics, Inc. | $10.44 | 594.7M | — | — | — | — | -5.61 | 1.15 | — | -0.72 | — | 1.15 | 0.00% | — | — | -19.08% | 5921.50% | -18.31% | 0.01 | — | 29.31 | 29.16 | 0.41 | -2605.00% | — | -2613.00% | -15.60% | -5.09 | 4123.87% | 0.00% | 0.00% | 0.75% | -0.57 | -0.81 | — | 15.77 |
| ENGN | enGene Holdings Inc. | $10.11 | 517.58M | — | — | — | — | -3.84 | 2.69 | — | -2.53 | -6.75 | 2.69 | 0.00% | — | — | -53.28% | -379.44% | -44.05% | 0.19 | -41.14 | 6.30 | 6.13 | 0.16 | 5685.00% | — | 10470.00% | -22.37% | -3.10 | -310.30% | 0.00% | 0.00% | 0.00% | -2.34 | -2.86 | — | 1.76 |
| KRRO | Korro Bio, Inc. | $12.13 | 114.23M | — | -2% | — | — | -2.38 | 1.24 | 87.71 | -1.33 | — | 1.24 | 100.00% | -4047.12% | -3680.36% | -50.61% | -158.39% | -37.32% | 0.28 | — | 8.79 | 8.54 | 0.12 | -8235.00% | — | 380.00% | -39.15% | -4.02 | -134.38% | 0.00% | 0.00% | 0.00% | -1.28 | -1.51 | 51.90 | -0.55 |
| LBRX | LB Pharmaceuticals Inc Co… | $24.01 | 607.43M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 97.81% | 65.95% | -159.37% | -0.04 | — | 3.56 | 3.45 | 0.31 | 90734.00% | — | 34410.00% | — | -6.54 | 54.75% | — | 0.00% | — | — | — | — | — |
| QSI | Quantum-Si incorporated | $0.96 | 187.03M | +4,402% | -8% | — | — | -1.83 | 0.86 | 60.41 | 0.11 | -41.45 | 0.86 | 52.32% | -3550.56% | -3303.04% | -41.48% | -452.86% | -36.99% | 0.06 | — | 11.99 | 11.60 | 0.35 | 441.00% | 18262.00% | -698.00% | -50.01% | -4.83 | -385.30% | 0.00% | 0.00% | 0.00% | 0.11 | 0.13 | -3.90 | -0.42 |
| RCKT | Rocket Pharmaceuticals, I… | $5.01 | 542.19M | — | — | — | — | -2.48 | 1.99 | — | -2.38 | — | 2.59 | 0.00% | — | — | -60.27% | -135.95% | -52.00% | 0.09 | -122.55 | 6.38 | 2.57 | 0.25 | -2637.00% | — | -1166.00% | -34.48% | -6.29 | -111.72% | 0.00% | 0.00% | 0.00% | -2.16 | -2.62 | — | -1.60 |
| SLDB | Solid Biosciences Inc. | $6.21 | 483.82M | — | — | — | — | -1.77 | 1.61 | — | -0.79 | — | 1.61 | 0.00% | — | — | -94.57% | -623.56% | -70.53% | 0.18 | -381.55 | 5.20 | 4.92 | 0.46 | -3665.00% | — | 519.00% | -45.50% | -3.31 | -483.87% | 0.00% | 0.00% | 6.07% | -0.74 | -0.96 | — | -4.69 |
About Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
- CEO
- Elisabet de los Pinos
- Employees
- 106
- Beta
- 0.46
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $7.01) − 1 = — (DCF, example).